Analgesic Efficacy and Acceptability of Fenoprofen Combined with Paracetamol and Compared with Dihydrocodeine Tartrate in General Practice

1978 ◽  
Vol 6 (5) ◽  
pp. 375-380 ◽  
Author(s):  
J E Murphy ◽  
J F Donald ◽  
A Layes Molla
Keyword(s):  
Chronic Pain ◽  
General Practice ◽  
Side Effects ◽  
Success Rate ◽  
Lower Incidence ◽  
Analgesic Efficacy ◽  
Patient Assessment ◽  
Patient Study ◽  
Single Blind

A single-blind between-patient study in general practice was made to examine the acceptability and analgesic efficacy of a combination of fenoprofen (200 mg) and paracetamol (500 mg) given 3 to 4 times daily for a period of 4 to 14 days in the treatment of acute and chronic pain. The combination was compared with dihydrocodeine tartrate (30 mg) in two groups of 75 patients suffering from a wide variety of presenting conditions, including osteoarthritis, spondylitis, lumbago,' sciatica, non-articular rheumatism and trauma. Clinical and patient assessment indicated that the combination was an effective analgesic combination, significantly better in success rate than dihydrocodeine tartrate and with a much lower incidence of side-effects (13% of patients receiving fenoprofen and paracetamol reported side-effects compared to 37% for the dihydrocodeine group). The combination demonstrated particular success in the treatment of non-articular rheumatism.

scholarly journals Opioid Analgesia: Perspectives on Right Use and Utility

2007 ◽  
Vol 3;10 (5;3) ◽  
pp. 479-491 ◽  
Author(s):  
Jane C. Ballantyne
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Side Effects ◽  
Clinical Decision Making ◽  
Analgesic Efficacy ◽  
Clinical Decision ◽  
Opioid Analgesia ◽  
Opioid Treatment

The ability of opioids to effectively and safely control acute and cancer pain has been one of several arguments used to support extending opioid treatment to patients with chronic pain, against a backdrop of considerable caution that has been based upon fears of addiction. Of course, opioids may cause addiction, but the “principle of balance” may justify that “…efforts to address abuse should not interfere with legitimate medical practice and patient care.” Yet, situations are increasingly encountered in which opioid-maintained patients are refractory to analgesia during periods of pain, or even during the course of chronic treatment. The real question is whether analgesic efficacy of opioids can be maintained over time. Overall, the evidence supporting long-term analgesic efficacy is weak. The putative mechanisms for failed opioid analgesia may be related to tolerance or opioid-induced hyperalgesia. Advances in basic sciences may help in understanding these phenomena, but the question of whether long-term opioid treatment can improve patients’ function or quality of life remains a broader issue. Opioid side effects are well known, but with chronic use, most (except constipation) subside. Still, side effects can negatively affect the outcomes and continuity of therapy. This paper addresses 1) what evidence supports the long-term utility of opioids for chronic pain; 2) how side effects may alter quality of life; 3) the nature of addiction and why it is different in pain patients, and 4) on what grounds could pain medication be denied? These questions are discussed in light of patients’ rights, and warrant balancing particular responsibilities with risks. These are framed within the Hippocratic tradition of “producing good for the patient and protecting from harm,” so as to enable 1) more informed clinical decision making, and 2) progress towards right use and utility of opioid treatment for chronic pain. Key Words: Opioids, chronic pain, addiction, side effects, utility, ethics

A Single-Blind Comparative Clinical Trial of Lymecycline and Amoxycillin in the Treatment of Acute Bronchitis in General Practice

1976 ◽  
Vol 4 (1) ◽  
pp. 64-68 ◽  
Author(s):  
J E Murphy ◽  
J F Donald ◽  
A L Molla
Keyword(s):  
Clinical Trial ◽  
General Practice ◽  
Side Effects ◽  
General Practitioners ◽  
Statistical Significance ◽  
Acute Bronchitis ◽  
Sputum Volume ◽  
Blind Comparison ◽  
Single Blind ◽  
Symptoms And Signs

A single-blind comparison of lymecycline and amoxycillin was performed by three general practitioners in the treatment of acute bronchitis, A total of 132 patients were treated for seven days with lymecycline (204 mg) two capsules twice daily or amoxycillin 250 mg three times daily. Symptoms and signs assessed were cough, dyspnoea, sputum volume, purulence of sputum and temperature. Both drugs brought about a statistically significant improvement. For all parameters the improvements seen with lymecycline were superior to those seen with amoxycillin although in no case did any of these reach statistical significance. However, in the case of purulent sputum those patients receiving lymecycline showed improvement which reached borderline significance (0.05 < p < 0.1) as compared with amoxycillin. Side-effects in the case of both drugs were negligible.

A General Practice Trial of an Amoxycillin/Flucloxacillin Combination (Suprapen) in Proven Bacterial Infections

1979 ◽  
Vol 7 (6) ◽  
pp. 531-534 ◽  
Author(s):  
N A Kritzinger
Keyword(s):  
General Practice ◽  
Side Effects ◽  
Bacterial Infection ◽  
Clinical Response ◽  
Success Rate ◽  
Bacterial Infections ◽  
Practice Trial ◽  
Satisfactory Clinical Response

Ninety-three cases of proven bacterial infection occurring in general practice were treated with an amoxycillin/flucloxacillin combination. There was a satisfactory clinical response in 98% of patients and an overall bacteriological success rate of 95.7%. Eleven patients (9.1%) complained of side-effects but withdrawal of the combination was necessary in only one patient who developed a rash.

A Comparison of Pivmecillinam/Pivampicillin and Amoxycillin in Acute Exacerbations of Chronic Bronchitis

1987 ◽  
Vol 15 (2) ◽  
pp. 115-120
Author(s):  
M. J. Atkins ◽  
D. J. Talbot
Keyword(s):  
General Practice ◽  
Side Effects ◽  
Chronic Bronchitis ◽  
Peak Expiratory Flow ◽  
Standard Therapy ◽  
Flow Rates ◽  
Parallel Group ◽  
Acute Exacerbations ◽  
Single Blind ◽  
Expiratory Flow Rates

Courses of 7 days on either 200 mg pivmecillinam/250 mg pivampicillin given twice daily or 250 mg amoxycillin given three times daily were compared in 3783 general practice patients with acute exacerbations of chronic bronchitis in a single-blind parallel group study. Patients on pivmecillinam/pivampicillin had significantly more ‘excellent’ responses, although there was no difference in overall response between treatments. Post-treatment sputum colour and consistency and peak expiratory flow rates were significantly better with pivmecillinam/pivampicillin. The incidence of side-effects was the same for both groups (approximately 10%), although significantly more patients reported lower gastro-intestinal problems with amoxycillin. Treatment was withdrawn due to side-effects in 47 (2.5%) patients on pivmecillinam/pivampicillin and 51 (2.7%) patients on amoxycillin. Amoxycillin is a standard therapy in the treatment of patients with acute exacerbations of chronic bronchitis. In this study, however, it was shown that pivmecillinam/pivampicillin offers benefits over amoxycillin in these patients.

A Double-Blind Controlled Trial of ‘Vivalan’ (Viloxazine Hydrochloride) and Imipramine Hydrochloride in the Treatment of Depression in General Practice

1974 ◽  
Vol 2 (4) ◽  
pp. 260-264 ◽  
Author(s):  
P F C Bayliss ◽  
A R Dewsbury ◽  
J F Donald ◽  
J W Harcup ◽  
M Mayer ◽  
...  
Keyword(s):  
General Practice ◽  
Side Effects ◽  
General Practitioners ◽  
Side Effect ◽  
Controlled Trial ◽  
Depressive Illness ◽  
Double Blind ◽  
Patient Study ◽  
Treatment Of Depression ◽  
Imipramine Hydrochloride

One hundred and twenty-three patients with mild to moderate depressive illness were entered into a double-blind between-patient study of viloxazine hydrochloride (150 mg/day, expressed as base) and imipramine hydrochloride (75 mg/day, expressed as salt) by nine general practitioners. Sixty-two took viloxazine and sixty-one took imipramine. Both drugs produced a statistically highly significant improvement in both the depressive and anxiety symptoms over the period of the study, an effect being seen as early as the seventh day of treatment. Viloxazine produced fewer side-effects than imipramine, in particular significantly less drowsiness and dry mouth. The only side-effect seen with viloxazine was an upper gastro-intestinal disturbance with nausea and occasional vomiting, but this was transient. It is concluded that viloxazine hydrochloride is an effective anti-depressant in mild to moderate cases of depression in general practice and has the advantage of fewer side-effects than imipramine. The absence of sedation with viloxazine is of particular value in the treatment of ambulant patients.

A Comparison between Gastrils and Aludrox in the Treatment of Gastric Hyperacidity in General Practice

1982 ◽  
Vol 10 (6) ◽  
pp. 437-442 ◽  
Author(s):  
Gabriel Jaffé ◽  
Jack J Grimshaw
Keyword(s):  
General Practice ◽  
Side Effects ◽  
Beneficial Effect ◽  
Crossover Study ◽  
Clinical Evaluation ◽  
Gastric Hyperacidity ◽  
Receive Treatment ◽  
To Receive ◽  
Single Blind

A single-blind multicentre crossover study was carried out in general practice of 47 patients with symptoms due to hyperacidity. Patients were allocated at random to receive treatment either with Gastrils® for the first 2 weeks followed by Aludrox® tablets for the second 2 weeks, or with Aludrox tablets for the first 2 weeks followed by Gastrils for the second 2 weeks. Clinical evaluation took place initially, after the first 2 weeks treatment and after the second 2 weeks treatment. The efficacy and acceptability of both preparations were compared, likewise the flavours of different Gastrils packs. Analysis of the results showed that peppermint flavoured Gastrils were significantly preferred to Aludrox tablets, and a peppermint flavour to a banana flavour. Side-effects were significantly more prevalent with Aludrox tablets. Differences in antacid response were similar, but numerically, if not statistically significantly, Gastrils had a more beneficial effect.

Bipolar radiofrequency induced thermotherapy and 1064 nm Nd:Yag laser in endovenous occlusion of insufficient veins: short term follow up results

VASA ◽  
2011 ◽  
Vol 40 (3) ◽  
pp. 235-240 ◽  
Author(s):  
Krnic ◽  
Sucic
Keyword(s):  
Side Effects ◽  
Success Rate ◽  
Nd:Yag Laser ◽  
Main Stem ◽  
Short Term ◽  
Main Trunk ◽  
Bipolar Radiofrequency ◽  
Saphenous Veins ◽  
Skin Redness ◽  
Complete Failure

Background: The aim of this study is to report our results in main stem vein closure using the bipolar radiofrequency induced thermotherapy (RFITT) system and the 1064nm Nd:Yag laser. Patients and methods: 44 incompetent main stem veins (37 great saphenous veins, one lesser saphenous vein, and 6 anterior accessory saphenous veins) in 29 patients were treated using RFITT. 53 incompetent main stem veins (45 great saphenous veins, 4 lesser saphenous veins, and 4 anterior accessory saphenous veins) in 43 patients were treated endovenously with 1064 nm Nd:Yag laser. All patients underwent postoperative duplex scanning within a month after procedure, as well as a short interview regarding postoperative discomfort. Results: In main stem veins treated with RFITT, the success rate within the first month was 86,4 % (38 out of 44 veins). Complete failure rate was 13,6 % (6 out of 44 veins). In 53 main stem veins treated by 1064 nm Nd:Yag laser, the success rate was 100 %, consisting of 98,1 % complete success (52/53 veins), and 1,9 % partial success (1/53 veins). None of the patients treated with RFITT experienced postoperative adverse effects, whereas 13/43 (30,2 %) patients treated with laser had to use oral analgesics after the treatment, and 21/43 (48,8 %) patients reported transient skin changes, such as bruising or skin redness. Conclusions: RFITT system was fairly efficient in the short term for closure of main trunk veins, whereas longer term results are still scarce. Postoperative side effects of RFITT were minimal. 1064nm Nd:Yag laser, according to short term results, proved to be very effective for main stem vein closure. Postoperative side effects related to 1064 nm Nd:Yag endovenous laser treatment proved to be minor, transient, and acceptable.

RESEARCH EPIDURAL ANALGESIA TO PAIN RELIEF ON LABOR PROGRESS

2012 ◽  
pp. 31-41
Author(s):  
Quang Thuy Phung ◽  
Ngoc Thanh Cao ◽  
Quang Vinh Truong
Keyword(s):  
Chronic Pain ◽  
Side Effects ◽  
Pain Relief ◽  
Epidural Anesthesia ◽  
Good Condition ◽  
Cervical Dilation ◽  
Normal Birth ◽  
Normal Limits ◽  
Constant Pain ◽  
Background Pain

Background: Pain during labor as pain in the fracture is not treated, chronic pain, so pain is very essential issues to be studied. Epidural anesthesia (NMC) has many advantages over spinal anesthesia in constant pain. Study objectives: 1. Assessing the effects analgesia by epidural anesthesia during labor. 2. Assessing progress and final results of labor for pregnant women and fetuses. Materials and Methods: The study described 37 pregnant from 38 to less than 42 weeks had a positive phase of labor to pain relief by continuous epidural anesthesia method, with cervical dilation between 3 cm and 4 cm. Results: Women feel very satisfied (67.5%) on methods of natural pain relief during labor. Most women deliver normally (73%). Evolution of the cervix takes place smoothly. Duration of labor within the normal birth. Breast sucking good condition accounted for 86.5% rate, the reflecting normal 94.6%. Conclusions: This is the effective method of pain relief during labor birth. Duration of labor in normal limits. Side effects occur less and can be well controlled. Keywords: epidural anesthesia; relief pain on labor.

Mesenchymal Stem Cells and their Exosomes: Promising Therapeutics for Chronic Pain

2019 ◽  
Vol 14 (8) ◽  
pp. 644-653 ◽  
Author(s):  
Jinxuan Ren ◽  
Na Liu ◽  
Na Sun ◽  
Kehan Zhang ◽  
Lina Yu
Keyword(s):  
Stem Cells ◽  
Chronic Pain ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Side Effects ◽  
Human Life ◽  
Analgesic Effects ◽  
Pain Models ◽  
Inflammatory Drugs ◽  
Anxiety Depression

Chronic pain is a common condition that seriously affects the quality of human life with variable etiology and complicated symptoms; people who suffer from chronic pain may experience anxiety, depression, insomnia, and other harmful emotions. Currently, chronic pain treatments are nonsteroidal anti-inflammatory drugs and opioids; these drugs are demonstrated to be insufficient and cause severe side effects. Therefore, research into new therapeutic strategies for chronic pain is a top priority. In recent years, stem cell transplantation has been demonstrated to be a potent alternative for the treatment of chronic pain. Mesenchymal stem cells (MSCs), a type of pluripotent stem cell, exhibit multi-directional differentiation, promotion of stem cell implantation, and immune regulation; they have also been shown to exert analgesic effects in several chronic pain models. Exosomes produced by MSCs have been demonstrated to relieve painful symptoms with fewer side effects. In this review, we summarize the therapeutic use of MSCs in various chronic pain studies. We also discuss ways to enhance the treatment effect of MSCs. We predict in the future, cell-free therapies for chronic pain will develop from exosomes secreted by MSCs.

scholarly journals Buprenorphine: Far Beyond the “Ceiling”

Biomolecules ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 816
Author(s):  
Rosmara Infantino ◽  
Consalvo Mattia ◽  
Pamela Locarini ◽  
Antonio Luigi Pastore ◽  
Sabatino Maione ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Neuropathic Pain ◽  
Drug Abuse ◽  
Side Effects ◽  
National Health System ◽  
Analgesic Drugs ◽  
Third Line ◽  
Dynamic Profile

Chronic pain, including neuropathic pain, represents an untreated disease with important repercussions on the quality of life and huge costs on the national health system. It is well known that opioids are the most powerful analgesic drugs, but they represent the second or third line in neuropathic pain, that remain difficult to manage. Moreover, these drugs show several side effects that limit their use. In addition, opioids possess addictive properties that are associated with misuse and drug abuse. Among available opioids compounds, buprenorphine has been suggested advantageous for a series of clinical reasons, including the effectiveness in neuropathic pain. Some properties are partly explained by its unique pharmacological characteristics. However, questions on the dynamic profile remain to be answered. Pharmacokinetics optimization strategies, and additional potentialities, are still to be explored. In this paper, we attempt to conceptualize the potential undiscovered dynamic profile of buprenorphine.

Sign in / Sign up

Export Citation Format

Share Document